Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Gerhild Becker
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, G. Becker wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Editorial Patients with advanced disease: the value of patient reported outcomes. 2014

Gaertner, Jan / Becker, Gerhild. ·Department of Palliative Care, University Medical Center Freiburg, Freiburg i.Br., Germany. ·Oncol Res Treat · Pubmed #24613902.

ABSTRACT: -- No abstract --

2 Review Stereotactic radiotherapy in the liver hilum. Basis for future studies. 2012

Zamboglou, C / Messmer, M-B / Becker, G / Momm, F. ·Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Str. 3, 79106, Freiburg, Germany. ·Strahlenther Onkol · Pubmed #22194027.

ABSTRACT: BACKGROUND: A basis for future trials with stereotactic body radiotherapy (SBRT) for tumors of the liver hilum should be established. Thus, dosage concepts, planning processes, and dose constraints as well as technical innovations are summarized in this contribution. METHODS: On the background of our own data, the current literature was reviewed. The use of SBRT in the most common tumors of the liver hilum (pancreatic cancer and Klatskin tumors) was investigated. Dose constraints were calculated in 2 Gy standard fractionation doses. RESULTS: A total of 8 pilot or phase I/II studies about SBRT in the liver hilum were identified. In recent years, the SBRT technique has developed very quickly from classical stereotactic body frame radiotherapy to IGRT techniques including gating and tracking systems. In the studies using classical body frame technique, patients experienced considerable toxicities (duodenal ulcer/perforation) as compared to tolerable side effects in IGRT studies (<10% grade 3 and 4 toxicities). Dose constraints for duodenum, liver, kidneys, colon, and spinal cord were derived from the investigated studies. Survival and local tumor control data are very heterogeneous: median survival in these patients with locally advanced pancreatic or Klatskin tumors ranges between 5 and 32 months. Excellent local tumor control rates of about 80% over 24 months were achieved using SBRT. CONCLUSION: Despite a few negative results, SBRT seems to be a promising technique in the treatment of tumors of the liver hilum. Highest precision in diagnostics, positioning, and irradiation as well as strict dose constraints should be applied to keep target volumes as small as possible and side effects tolerable.